Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

An early increase in serum TTR levels on Day 28 of dosing was associated with reduced all-cause mortality (ACM) in univariate analysis, an association which persisted in multivariate analysis ...

Alnylam Pharmaceuticals (NASDAQ:ALNY) on Saturday released additional data from its Phase 3 HELIOS-B trial, which evaluated ...

While receiving treatment for a car accident ten years ago, Mr Chua learnt that he had an abnormal build-up of protein in his ...

About 150 people in Singapore have transthyretin amyloid cardiomyopathy. Read more at straitstimes.com. Read more at ...

While receiving treatment for a car accident ten years ago, Mr Chua learnt that he had an abnormal build-up of protein in his ...

London, UK, Monday 7 April 2025 – Today, AstraZeneca announced that the Scottish Medicines Consortium (SMC) has accepted Wainzua (eplontersen) for use within NHS Scotland for the treatment of ...

Hereditary ATTR (ATTRv) amyloidosis occurs when a person is born with mutations in the TTR gene, which causes the liver to produce structurally abnormal transthyretin (TTR) protein with a propensity ...

which causes the liver to produce structurally abnormal transthyretin (TTR) protein with a propensity to misfold. These damaged proteins build up as amyloid in the body, causing serious ...

The drug, called Amvuttra (vutrisiran), is made by Alnylam Pharmaceuticals Inc. and is used to treat transthyretin amyloid cardiomyopathy. ATTR-CM is a disease in which harmful proteins build up ...